These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Natural killer cell number and activity in remission phase of systemic connective tissue diseases. Markeljević J; Marusić M; Uzarević B; Petrovecki M; Cikes N; Babić-Naglić D; Horvat Z J Clin Lab Immunol; 1991 Jul; 35(3):133-8. PubMed ID: 1668766 [TBL] [Abstract][Full Text] [Related]
3. Relationship of Sjögren's syndrome to other connective tissue and autoimmune disorders. Theander E; Jacobsson LT Rheum Dis Clin North Am; 2008 Nov; 34(4):935-47, viii-ix. PubMed ID: 18984413 [TBL] [Abstract][Full Text] [Related]
4. Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome. Pedersen BK; Oxholm P; Manthorpe R; Andersen V Clin Exp Immunol; 1986 Jan; 63(1):1-7. PubMed ID: 3485480 [TBL] [Abstract][Full Text] [Related]
5. [Significance of antinuclear antibodies in the diagnosis of connective tissue diseases]. Bambara LM; Biasi D; Caramaschi P; Codella O; Corrocher R; Serpelloni G; De Sandre G Recenti Prog Med; 1985 Feb; 76(2):102-9. PubMed ID: 3887516 [No Abstract] [Full Text] [Related]
6. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Green MR; Kennell AS; Larche MJ; Seifert MH; Isenberg DA; Salaman MR Clin Exp Immunol; 2005 Jul; 141(1):165-73. PubMed ID: 15958083 [TBL] [Abstract][Full Text] [Related]
7. [Difficulties in differential diagnosis of Sjögren's syndrome and systemic lupus erythematosus]. Krawiec P; Batko B; Skura A; Adamek-Guzik T; Cześnikiewicz-Guzik M; Krzanowski M; Rydz-Stryszowska I; Ryszawa N; Guzik TJ Przegl Lek; 2006; 63(5):278-83. PubMed ID: 17036505 [TBL] [Abstract][Full Text] [Related]
8. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Park YW; Kee SJ; Cho YN; Lee EH; Lee HY; Kim EM; Shin MH; Park JJ; Kim TJ; Lee SS; Yoo DH; Kang HS Arthritis Rheum; 2009 Jun; 60(6):1753-63. PubMed ID: 19479851 [TBL] [Abstract][Full Text] [Related]
9. Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes. Struyf NJ; Snoeck HW; Bridts CH; De Clerck LS; Stevens WJ Ann Rheum Dis; 1990 Sep; 49(9):690-3. PubMed ID: 1700674 [TBL] [Abstract][Full Text] [Related]
10. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Kojo S; Adachi Y; Keino H; Taniguchi M; Sumida T Arthritis Rheum; 2001 May; 44(5):1127-38. PubMed ID: 11352245 [TBL] [Abstract][Full Text] [Related]
12. Natural killer cell activity in the systemic connective tissue diseases. Gonzalez-Amaro R; Alcocer-Varela J; Alarcón-Segovia D J Rheumatol; 1988 Aug; 15(8):1223-8. PubMed ID: 3263500 [TBL] [Abstract][Full Text] [Related]
13. Altered circadian rhythms of natural killer (NK) cell activity in patients with autoimmune rheumatic diseases. Masera RG; Carignola R; Staurenghi AH; Sartori ML; Lazzero A; Griot G; Angeli A Chronobiologia; 1994; 21(1-2):127-32. PubMed ID: 7924633 [TBL] [Abstract][Full Text] [Related]
14. [Increased numbers of large granular lymphocytes in the peripheral blood in selected inflammatory rheumatic diseases]. Rovenský J; Tóth J; Rauová L; Lukác J; Zlnay D Vnitr Lek; 1991 Jun; 37(6):572-7. PubMed ID: 1897139 [TBL] [Abstract][Full Text] [Related]
15. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment. Ebo D; DeClerck LS; Bridts CH; Stevens WJ In Vivo; 1994; 8(4):577-80. PubMed ID: 7534494 [TBL] [Abstract][Full Text] [Related]
16. Characterization of peripheral natural killer cells in primary Sjögren's syndrome: impaired NK cell activity and low NK cell number. Izumi Y; Ida H; Huang M; Iwanaga N; Tanaka F; Aratake K; Arima K; Tamai M; Kamachi M; Nakamura H; Origuchi T; Kawakami A; Anderson P; Eguchi K J Lab Clin Med; 2006 May; 147(5):242-9. PubMed ID: 16697772 [TBL] [Abstract][Full Text] [Related]
17. Impaired release of natural killer cytotoxic factor in patients with primary Sjögren's syndrome. Pedersen BK; Oxholm P Clin Exp Immunol; 1988 May; 72(2):299-302. PubMed ID: 3409548 [TBL] [Abstract][Full Text] [Related]
18. Interferon and natural killer cells in systemic lupus erythematosus. Strannegård O; Hermodsson S; Westberg G Clin Exp Immunol; 1982 Nov; 50(2):246-52. PubMed ID: 6185256 [TBL] [Abstract][Full Text] [Related]
19. Comparison of antinuclear antibody and other immunohematological profiles among primary Sjögren's syndrome, secondary Sjögren's syndrome associated with rheumatoid arthritis or systemic lupus erythematosus, and corresponding systemic disease. Ichikawa Y; Takaya M; Shimizu H; Uchiyama M; Moriuchi J; Morita K; Hoshina Y; Horiki T Tokai J Exp Clin Med; 1993 Dec; 18(3-6):133-8. PubMed ID: 7701526 [TBL] [Abstract][Full Text] [Related]
20. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Amoura Z; Koutouzov S; Chabre H; Cacoub P; Amoura I; Musset L; Bach JF; Piette JC Arthritis Rheum; 2000 Jan; 43(1):76-84. PubMed ID: 10643702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]